Shenzhen Hepalink Acquires U.S. API Manufacturer Scientific Protein Laboratories
This article was originally published in PharmAsia News
Shenzhen Hepalink Pharmaceutical acquired 100% of the equity interest of Scientific Protein Laboratories (SLP), a U.S. leading manufacturer of heparin active pharmaceutical ingredients (APIs) for $2.075 billion Jan. 13.
You may also be interested in...
Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.
With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.